Tags: Drug.
Blinatumomab (MT103) is a drug that has anti-cancer properties. It belongs to a new class of constructed monoclonal antibodies bi-specific T-cell engagers (BiTEs) that exert action selectively and direct the human immune system to act against tumor cells. Blinatumomab specifically targets the CD19 antigen present on B cells.The drug was developed by a German-American company Micromet Inc. in cooperation with Lonza.
